Use of MVA to treat prostate cancer
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 11, 2011
Issued Date -
N/A
app pub date -
Oct 16, 2008
filing date -
Oct 18, 2007
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The invention relates to compositions, kits, and methods for cancer prophylaxis and therapy using recombinant MVA viruses encoding tumor-associated antigens, such as PSA and PAP. The recombinant MVA viruses can induce B- and T-cell responses. The recombinant MVA viruses can be administered prior to, at the same time as, or after a taxane.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully